Preclinical laboratory science has revealed multiple new targets for breast cancer
therapy. Clinical trials targeting key signaling pathways are underway and a number of new
drugs have been approved for treatment. Targeting of growth factor receptors by monoclonal
antibodies and tyrosine kinase inhibitors were among the first to be approved, but
new small molecules inhibiting the phosphatidylinositol 3-kinase signaling pathway have
also shown promise. This review will evaluate potential new targets and specifically targets
in hormone receptor positive and triple negative breast cancer.
Keywords: Breast cancer, estrogen receptor, growth factor receptors, mammalian target of rapamycin,
phosphatidylinositol 3-kinase, tyrosine kinase inhibitors.
Rights & PermissionsPrintExport